Cybin target raised at Oppenheimer after psilocybin data from Compass Pathways

In the early hours, Cybin was a notable gainer among the developers of psychedelic-based therapies after Oppenheimer increased its price target to $10 from $7 per share in the wake of Phase 2 data shared by COMPASS Pathways for COMP360 psilocybin therapy.

Topic Personality

Compound Psilocybin

Visit article

Category Press Release

Country Canada

Companies Featured

Cybin
Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.